1. Home
  2. DCGO vs LPCN Comparison

DCGO vs LPCN Comparison

Compare DCGO & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DocGo Inc.

DCGO

DocGo Inc.

HOLD

Current Price

$0.72

Market Cap

67.0M

Sector

Health Care

ML Signal

HOLD

Logo Lipocine Inc.

LPCN

Lipocine Inc.

HOLD

Current Price

$10.04

Market Cap

61.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DCGO
LPCN
Founded
2015
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Managed Health Care
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
67.0M
61.8M
IPO Year
2020
2011

Fundamental Metrics

Financial Performance
Metric
DCGO
LPCN
Price
$0.72
$10.04
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$3.33
$15.00
AVG Volume (30 Days)
668.5K
79.9K
Earning Date
01-01-0001
05-26-2026
Dividend Yield
N/A
N/A
EPS Growth
200.00
N/A
EPS
N/A
N/A
Revenue
$616,555,132.00
$11,198,144.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
492.80
52 Week Low
$0.66
$2.52
52 Week High
$3.18
$12.37

Technical Indicators

Market Signals
Indicator
DCGO
LPCN
Relative Strength Index (RSI) 41.52 62.99
Support Level $0.66 $2.89
Resistance Level $0.95 $10.80
Average True Range (ATR) 0.07 0.82
MACD 0.00 0.01
Stochastic Oscillator 35.87 83.18

Price Performance

Historical Comparison
DCGO
LPCN

About DCGO DocGo Inc.

DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. The company uses its care delivery platform to provide mobile health services, virtual care management, and ambulance services. It has three reporting segments: Mobile Health Services, Transportation Services, and Corporate. A majority of its revenue is generated from the Mobile Health Services segment, which includes various healthcare services performed at homes, offices, and other locations and event services such as on-site healthcare support at sporting events and concerts. Geographically, the company generates a majority of its revenue from the United States and the rest from the United Kingdom.

About LPCN Lipocine Inc.

Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.

Share on Social Networks: